Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2009;4(3):e4724.
doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6.

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

Diane E Bennett  1 , Ricardo J Camacho, Dan Otelea, Daniel R Kuritzkes, Hervé Fleury, Mark Kiuchi, Walid Heneine, Rami Kantor, Michael R Jordan, Jonathan M Schapiro, Anne-Mieke Vandamme, Paul Sandstrom, Charles A B Boucher, David van de Vijver, Soo-Yon Rhee, Tommy F Liu, Deenan Pillay, Robert W Shafer
Affiliations
Guideline

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

Diane E Bennett et al. PLoS One. 2009.

Abstract

Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programs. To accurately compare transmitted drug resistance rates across geographic regions and times, the World Health Organization has recommended the adoption of a consensus genotypic definition of transmitted HIV-1 drug resistance. In January 2007, we outlined criteria for developing a list of mutations for drug-resistance surveillance and compiled a list of 80 RT and protease mutations meeting these criteria (surveillance drug resistance mutations; SDRMs). Since January 2007, several new drugs have been approved and several new drug-resistance mutations have been identified. In this paper, we follow the same procedures described previously to develop an updated list of SDRMs that are likely to be useful for ongoing and future studies of transmitted drug resistance. The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9:695–702. - PubMed
    1. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis. 2006;19:607–614. - PubMed
    1. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22–32. - PubMed
    1. Bennett DE, Myatt M, Sutherland D, Bertagnolio S, Gilks C. World Health Organization recommendations for surveillance of transmitted HIV drug resistance in resource-limited countries where antiviral therapy is rapidly expanding. 2007. Antivir Ther Supplement. - PubMed
    1. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United Kingdom. J Acquir Immune Defic Syndr. 2008;49:196–204. - PubMed

Publication types

  NODES
twitter 2